Psychedelic therapy re-emerging as promising treatment for anxiety, PTSD and addiction (Dr. Evan Wood)
Renewed medical interest in the use of psychedelic drugs for anxiety, posttraumatic stress disorder (PTSD) and addiction has resulted in small research studies that show some success with the controlled use of these drugs, according to an analysis published in CMAJ (Canadian Medical Association Journal).
Psychedelic drugs are substances that have a strong effect on one's “conscious experience,” such as lysergic acid diethylamide (LSD), psilocybin, found in “magic mushrooms,” dimethyltryptamine (DMT), mescaline and methylenedioxymethamphetamine (MDMA).
“The re-emerging paradigm of psychedelic medicine may open clinical doors and therapeutic doors long closed,” writes Dr. Evan Wood, Professor of Medicine and Canada Research Chair, University of British Columbia, Vancouver, B.C., co-director of the Urban Health Research Initiative at the BC Centre for Excellence in HIV/AIDS, and co-authors Drs. Kenneth W. Tupper, Richard Yensen, and Matthew W. Johnson.
Ken, cardiac patient